Characterization of toxicokinetics and toxicodynamics with linear systems theory: Application to lead-associated cognitive decline

Environmental Health Perspectives

Volumn 109, Issue 4, 2001, Pages 361-368

  Links, Jonathan M ^a   Schwartz, Brian S ^a   Simon, David ^a   Bandeen Roche, Karen ^a   Stewart, Walter F ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Bone lead; Exposure assessment; Linear systems model; Toxicodynamics; Toxicokinetics

Indexed keywords

LEAD;

AREA UNDER THE CURVE; ARTICLE; BONE LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DYNAMICS; HALF LIFE TIME; LEAD BLOOD LEVEL; LINEAR SYSTEM; LONGITUDINAL STUDY; MATHEMATICAL MODEL; PRIORITY JOURNAL; THEORY; TOXICOKINETICS; X RAY FLUORESCENCE;

EID: 0035015587     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.01109361     Document Type: Article

References (25)

1. Links JM, Kensler TW, Groopman JD. Biomarkers and mechanistic approaches in molecular epidemiology. Annu Rev Public Health 16:83-103 (1995).
2. Smith TJ. Exposure-dose relationships. In: Exposure Assessment for Epidemiology and Hazard Control (Rappaport SM, Smith TJ, eds). Boca Raton, FL:Lewis Publishers, 1990;97-114.
3. Sato A, Endoh K, Johanson G. The use of models to investigate the toxicokinetic behavior of organic solvents. In: Exposure Assessment for Epidemiology and Hazard Control (Rappaport SM, Smith TJ, eds). Boca Raton, FL:Lewis Publishers, 1990;131-152.
4. Smith TJ. Pharmacokinetic models in the development of exposure indicators in epidemiology. Ann Occup Hyg 35:543-560 (1991).
5. Oppenheim AV, Schafer RW. Discrete-Time Signal Processing. Englewood Cliffs, NJ:Prentice Hall, 1989.
6. Rappaport SM. Assessment of long-term exposures to toxic substances in air. Ann Occup Hyg 35:61-121 (1991)
7. Bandeen-Roche K, Hall CB, Stewart WF, Zeger SL. Modelling disease progression in terms of exposure history. Stat Med 18:2899-2916 (1999).
8. Hu H, Milder FL, Burger DE. X-ray fluorescence: issues surrounding the application of a new tool for measuring burden of lead. Environ Res 49:295-317 (1989).
9. Todd AC, Chettle DR. In vivo X-ray fluorescence of lead in bone: review and current issues. Environ Health Perspect 102:172-177 (1994).
10. Hu H, Pepper L, Goldman R. Effect of repeated occupational exposure to lead, cessation of exposure, and chelation on levels of lead in bone. Am J Ind Med 20:723-735 (1991).
11. Fleming DEB, Chettle DR, Wetmur JG, Desnick RJ, Robin JP, Boulay D, Richard NS, Gordon CL, Webber CE. Effect of the d-aminolevulinate dehydratase polymorphism on the accumulation of lead in bone and blood in lead smelter workers. Environ Res 77:49-61 (1998).
12. Somervaille LJ, Chettle DR, Scott MC, Tennant DR, McKiernan MJ, Skilbeck A, Trethowan WN. In vivo tibia lead measurements as an index of cumulative exposure in occupationally exposed subjects. Br J Ind Med 45:174-181 (1988).
13. Cremin JD, Luck ML, Laughlin NK, Smith DR. Efficacy of succimer chelation for reducing brain lead in a primate model of human lead exposure. Toxicol Appl Pharmacol 161:283-293 (1999).
14. Hu H, Rabinowitz M, Smith D. Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Environ Health Perspect 106:1-8 (1998).
15. Schwartz BS, Stewart WF, Todd AC, Links JM. Predictors of dimercaptosuccinic acid chelatable lead and tibial lead in former organolead manufacturing workers. Occup Environ Med 56:22-29 (1999).
16. Stewart WF, Schwartz BS, Simon D, Bolla KI, Todd AC, Links J. Neurobehavioral function and tibial and chelatable lead levels in 543 former organolead workers. Neurology 52:1610-1617 (1999).
17. Schwartz BS, Stewart WF, Todd AC, Simon D, Links JM. Different associations of blood lead, DMSA-chelatable lead, and tibial lead levels with blood pressure in 543 former organolead manufacturing workers. Arch Environ Health 55:85-92 (2000).
18. Schwartz BS, Stewart WF, Kelsey KT, Simon D. Park S, Links JM, Todd AC. Associations of tibial lead levels with Bsml polymorphisms in the vitamin D receptor in former organolead manufacturing workers. Environ Health Perspect 108:199-211 (2000).
19. Schwartz BS, Stewart WF, Bolla KI, Simon D, Bandeen-Roche K, Gordon B, Links JM, Todd AC. Past adult lead exposure is associated with longitudinal decline in neurobehavioral function in 535 former organolead manufacturing workers. Neurology 55:1144-1150 (2000).
20. Nilsson U, Attewell R, Christoffersson JO, Schutz A, Ahlgren L. Skerfving S, Mattsson S. Kinetics of lead in bone and blood after end of occupational exposure. Pharmacol Toxicol 68:477-484 (1991).
21. Gerhardsson L, Attewell R, Chettle DR, Englyst V, Lundstrom NS, Nordberg GF, Nyhlin H, Scott MC, Todd AC. In vivo measurements of lead in bone in long-term exposed lead smelter workers. Arch Environ Hearth 48:147-156 (1993).
22. O'Flaherty EJ, lnskip MJ, Franklin CA, Durbin PW, Manton WI, Baccanale CL. Evaluation and modification of a physiologically based model of lead kinetics using data from a sequential isotope study in cynomolgus monkeys. Toxicol Appl Pharmacol 149:1-16 (1998).
23. Widzowski DV, Cory-Slechta DA. Homogeneity of regional brain lead concentrations. Neurotoxicology 15:295-308 (1994).
24. Szabo Z, Vosberg H, Sondhaus CA, Feinendegen LE. Model identification and estimation of organ-function parameters using radioactive tracers and the impulse-response function. Eur J Nucl Med 11:265-274 (1985).
25. 2 in the mouse after intravenous injection. Neurotoxicology 19:197-207 (1998).